roche

November 20, 2017November 20, 2017

FDA Approves Gazyva-Chemo Combo for Advanced Follicular Lymphoma

News

The U.S. Food and Drug Administration (FDA) has approved Roche’s Gazyva (obinutuzumab) in combination with chemotherapy as a first-line treatment for patients with advanced follicular lymphoma. The company said its ... Read more

September 26, 2017September 26, 2017

European Commission Approves Gazyvaro as First-Line Follicular Lymphoma Therapy

News

The European Commission has approved Roche’s Gazyvaro (obinutuzumab) for previously untreated patients with advanced follicular lymphoma. The treatment is approved in combination with chemotherapy and should be followed by Gazyvaro maintenance therapy. ... Read more

August 18, 2016August 18, 2016

Gazyva Combination Effective Therapy for NHL Patients Refractory to Rituxan

News

Results from the Phase 3 GADOLIN trial reveal that combining Gazyva (obinutuzumab) with bendamustine (available as Bendeka and Treanda) in patients with indolent non-Hodgkin’s lymphoma who are not responding to ... Read more

June 17, 2016June 17, 2016

EU Approves Gazyvaro (obinutuzumab) as a Treatment for Advanced Follicular Lymphoma

News

Roche announced that the European Commission has approved Gazyvaro (obinutuzumab), combined with bendamustine chemotherapy, to treat follicular lymphoma patients who have failed to respond to, or whose disease progressed despite, treatment with rituximab (MabThera) or a ... Read more

May 3, 2016May 3, 2016

CHMP Supports EU Approval of Obinutuzumab (Gazyvaro) to Treat Follicular Lymphoma

News

The EU Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Roche’s Gazyvaro (obinutuzumab), combined with bendamustine chemotherapy and then as monotherapy, to treat select patients with follicular lymphoma. The recommendation is as treatment for ... Read more